KYMERA THERAPEUTICS I

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

14 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

11 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

01 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

03 Nov 2022 07:05:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

03 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

20 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

13 Oct 2022 16:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

15 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming September Conferences

29 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Announces $150 Million Private Placement Equity Financing

19 Aug 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Second Quarter 2022 Results on August 9

27 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Strengthens Board of Directors with Appointment of People and Business Leader Leigh Morgan

08 Jul 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Peripheral T-Cell Lymphoma

01 Jun 2022 08:42:40 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present Pre-clinical Data at the EULAR 2022 Congress Showing STAT3 Degradation Blocked Th17 Development and Prevented Rheumatoid Arthritis

01 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

20 May 2022 07:30:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation

05 May 2022 08:00:02 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Quarter 2022 Financial Results and Provides a Business Update

03 May 2022 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report First Quarter 2022 Results and Announces Participation at Upcoming Investor Conferences

19 Apr 2022 08:00:02 By Nasdaq GlobeNewswire